Search Results

There are 43125 results for: content related to: Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies

  1. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 27, Issue S1, June 2012, Pages: S1–S523,

    Article first published online : 19 JUN 2012, DOI: 10.1002/mds.25051

  2. Development of a physiologically based pharmacokinetic/pharmacodynamic model to identify mechanisms contributing to entacapone low bioavailability

    Biopharmaceutics & Drug Disposition

    Volume 36, Issue 9, December 2015, Pages: 587–602, Saeed Alqahtani and Amal Kaddoumi

    Article first published online : 24 DEC 2015, DOI: 10.1002/bdd.1986

  3. Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets

    Movement Disorders

    Volume 12, Issue 6, November 1997, Pages: 935–945, Lance A. Smith, Ariel Gordin, Dr. Peter Jenner and C. David Marsden

    Article first published online : 4 NOV 2004, DOI: 10.1002/mds.870120616

  4. Entacapone in combination with standard or controlled-release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease

    European Journal of Neurology

    Volume 2, Issue 4, September 1995, Pages: 341–347, S. Kaakkola, H. Teräväinen, S. Ahtila, M. Karlsson, T. Naukkarinen, H. Rita and A. Gordin

    Article first published online : 20 JAN 2011, DOI: 10.1111/j.1468-1331.1995.tb00137.x

  5. You have free access to this content
    Entacapone improves the availability of l-dopa in plasma by decreasing its peripheral metabolism independent of l-dopa/carbidopa dose

    British Journal of Clinical Pharmacology

    Volume 54, Issue 4, October 2002, Pages: 363–371, Helena Heikkinen, Anu Varhe, Tarmo Laine, Jaakko Puttonen, Marjo Kela, Seppo Kaakkola and Kari Reinikainen

    Article first published online : 23 OCT 2002, DOI: 10.1046/j.1365-2125.2002.01654.x

  6. Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug

    European Journal of Neurology

    Volume 11, Issue 9, September 2004, Pages: 593–606, L. Brusa, A. Bassi, G. Lunardi, E. Fedele, A. Peppe, A. Stefani, P. Pasqualetti, P. Stanzione and M. Pierantozzi

    Article first published online : 15 SEP 2004, DOI: 10.1111/j.1468-1331.2004.00860.x

  7. Pooled analysis of phase III with entacapone in Parkinson's disease

    Acta Neurologica Scandinavica

    Volume 130, Issue 4, October 2014, Pages: 239–247, M. Kuoppamäki, M. Vahteristo, J. Ellmén and K. Kieburtz

    Article first published online : 3 SEP 2014, DOI: 10.1111/ane.12278

  8. You have free access to this content
    Pharmacodynamic Response of Entacapone in Rats after Administration of Entacapone Formulations and Prodrugs with Varying Bioavailabilities

    Pharmacology & Toxicology

    Volume 90, Issue 6, June 2002, Pages: 327–332, Markus Forsberg, Jouko Savolainen, Tomi Järvinen, Jukka Leppänen, Jukka Gynther and Pekka T. Männistö

    Article first published online : 1 JUL 2002, DOI: 10.1034/j.1600-0773.2002.900606.x

  9. Twelve-month safety of entacapone in patients with Parkinson’s disease

    European Journal of Neurology

    Volume 8, Issue 1, January 2001, Pages: 53–60, V. V. Myllylä, E.-R. Kultalahti, H. Haapaniemi, M. Leinonen and FILOMEN Study Group

    Article first published online : 21 DEC 2001, DOI: 10.1046/j.1468-1331.2001.00168.x

  10. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)

    Acta Neurologica Scandinavica

    Volume 105, Issue 4, April 2002, Pages: 245–255, W. H. Poewe, G. Deuschl, A. Gordin, E.-R. Kultalahti, M. Leinonen and the Celomen Study Group

    Article first published online : 3 APR 2002, DOI: 10.1034/j.1600-0404.2002.1o174.x

  11. Effects of aqueous solubility and dissolution characteristics on oral bioavailability of entacapone

    Drug Development Research

    Volume 49, Issue 4, April 2000, Pages: 238–244, Jouko Savolainen, Markus Forsberg, Hannu Taipale, Pekka T. Männistö, Kristiina Järvinen, Jukka Gynther, Pekka Jarho and Tomi Järvinen

    Article first published online : 12 JUN 2000, DOI: 10.1002/1098-2299(200004)49:4<238::AID-DDR2>3.0.CO;2-V

  12. You have free access to this content
    Evidence-Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease

    CNS Neuroscience & Therapeutics

    Volume 14, Issue 1, Spring 2008, Pages: 83–93, Andrew J. Lees

    Article first published online : 14 MAR 2008, DOI: 10.1111/j.1527-3458.2007.00035.x

  13. Catechol-O-methyltransferase inhibitors: Clinical potential in the treatment of Parkinson's disease

    Drug Development Research

    Volume 42, Issue 1, September 1997, Pages: 1–25, Jasper Dingemanse

    Article first published online : 6 DEC 1998, DOI: 10.1002/(SICI)1098-2299(199709)42:1<1::AID-DDR1>3.0.CO;2-I

  14. Bimodal administration of entacapone in Parkinson’s disease patients improves motor control

    European Journal of Neurology

    Volume 15, Issue 3, March 2008, Pages: 268–273, L. Bet, S. R. Bareggi, F. Pacei, G. Bondiolotti, G. Meola and A. H. V Schapira

    Article first published online : 14 FEB 2008, DOI: 10.1111/j.1468-1331.2007.02043.x

  15. Poster session 1: A. Basic science, genetics, neuropharmacology, Parkinson's Disease

    Movement Disorders

    Volume 17, Issue S5, November 2002, Pages: S17–S64,

    Article first published online : 21 OCT 2002, DOI: 10.1002/mds.10349

  16. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: A randomized crossover clinical trial

    Annals of Neurology

    Volume 69, Issue 1, January 2011, Pages: 111–118, Jean-Christophe Corvol, Cécilia Bonnet, Fanny Charbonnier-Beaupel, Anne-Marie Bonnet, Marie-Hélène Fiévet, Agnès Bellanger, Emmanuel Roze, Gayané Meliksetyan, Mouna Ben Djebara, Andreas Hartmann, Lucette Lacomblez, Cédric Vrignaud, Noël Zahr, Yves Agid, Jean Costentin, Jean-Sébastien Hulot and Marie Vidailhet

    Article first published online : 28 JAN 2011, DOI: 10.1002/ana.22155

  17. You have free access to this content
    Entacapone promotes cAMP-dependent colonic Cl secretion in rats

    Neurogastroenterology & Motility

    Volume 23, Issue 7, July 2011, Pages: 657–e277, L.-S. Li, L.-F. Zheng, J.-D. Xu, T. Ji, H. Guo, X.-F. Li, Y. Li, Y. Zhang and J.-X. Zhu

    Article first published online : 19 APR 2011, DOI: 10.1111/j.1365-2982.2011.01715.x

  18. Catechol-O-Methyltransferase (COMT) Inhibitors in Parkinson's Disease

    Journal of the American Geriatrics Society

    Volume 48, Issue 6, June 2000, Pages: 692–698, Cheryl Waters

    Article first published online : 27 APR 2015, DOI: 10.1111/j.1532-5415.2000.tb04732.x

  19. The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF

    Movement Disorders

    Volume 25, Issue 3, 15 February 2010, Pages: 363–367, Maria Nord, Peter Zsigmond, Anita Kullman, Kerstin Årstrand and Nil Dizdar

    Article first published online : 13 JAN 2010, DOI: 10.1002/mds.22613

  20. You have free access to this content
    Cost-Effectiveness Analysis of Entacapone in Parkinson's Disease: A Markov Process Analysis

    Value in Health

    Volume 4, Issue 4, July 2001, Pages: 316–328, Mark J. C. Nuijten, Peter Van Iperen, Cynthia Palmer, Bob J. Van Hilten and Edward Snyder

    Article first published online : 28 JUN 2008, DOI: 10.1046/j.1524-4733.2001.44037.x